Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Randomized, Controlled, Multicenter Clinical Trial of Apatinib Plus CIK as the Third Line Therapy for Patients With Advanced Gastric Cancer

NCT02485015 is registered in ClinicalTrials.gov with The First People's Hospital of Changzhou as lead sponsor.

NCT NCT02485015
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02485015 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Randomized, Controlled, Multicenter Clinical Trial of Apatinib Plus CIK as the Third Line Therapy for Patients With Advanced Gastric Cancer
Lead sponsor
The First People's Hospital of Changzhou
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 30, 2015
Completion date
June 30, 2033
Enrollment
80 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

stomach neoplasms